Is Kodiak Sciences Inc. (KOD) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 4.6% / 30% | 11.1% / 30% | 0.0% / 30% | N/A | ✓ HALAL |
| DJIM | 4.6% / 33% | 11.1% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| MSCI | 21.0% / 33% | 50.1% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 4.6% / 33% | 11.1% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| FTSE | 21.0% / 33% | 50.1% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -207.9% | |
| Return on Assets (ROA) | -47.2% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$117M |
| Free Cash Flow | -$118M |
| Total Debt | $70M |
| Debt-to-Equity | 262.5 |
| Current Ratio | 1.8 |
| Total Assets | $336M |
Price & Trading
| Last Close | $39.76 |
| 50-Day MA | $25.23 |
| 200-Day MA | $17.07 |
| Avg Volume | 744K |
| Beta | 2.7 |
|
52-Week Range
$1.92
| |
About Kodiak Sciences Inc. (KOD)
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD. The company's preclinical stage product candidate includes KSI-501, an anti- interleukin-6 (IL-6) and VEGF-trap bispecific antibody biopolymer conjugate for high prevalence retinal vascular diseases; and KSI-101 (KSI-501P), an unconjugated bispecific protein targeting IL-6 and VEGF developed for patients who have retinal fluid and inflammation. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Kodiak Sciences Inc. (KOD) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Kodiak Sciences Inc. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Kodiak Sciences Inc.'s debt ratio?
Kodiak Sciences Inc.'s debt ratio is 4.6% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 21.0%.
What are Kodiak Sciences Inc.'s key financial metrics?
Kodiak Sciences Inc. has a market capitalization of $2.3B. Return on equity stands at -207.9%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.